What guidance did BillionToOne's management provide for the next earnings period?

What is BillionToOne's gross profit margin?

What were the key takeaways from BillionToOne's earnings call?

What is the revenue and EPS growth rate for BillionToOne year over year?

What factors drove the changes in BillionToOne's revenue and profit?

What does BillionToOne do and what are its main business segments?

What is BillionToOne's latest dividend and current dividend yield?

Did BillionToOne beat or miss consensus estimates last quarter?

- **Record Q4 Growth**: 113% YoY revenue to $96.1 million, driven by 47% test volume and ASP growth.
- **Rule of 100 Achievement**: Full-year 2025 revenue up 100% with 13% EBITDA margin.
- **Gross Margin Expansion**: 71.4% in Q4, up 14.3 percentage points YoY.
- **Landmark United Contract**: In-network agreement to accelerate test adoption and ASPs.
- **2026 Guidance**: $430-445 million revenue (41-46% growth) with continued profitability.
- **Oncology Innovation**: Launch of PGx and CH add-ons, MolDX coverage submission for Northstar Response.

**【CEO Summary Section】**
- Achieved 113% year-over-year (YoY) revenue growth in Q4 2025, reaching $96.1 million, driven by 47% test volume growth and 47% average selling price (ASP) increase.
- Full-year 2025 revenue of $305.1 million reflected 100% YoY growth, with a Rule of 100 performance (100% revenue growth and 13% adjusted EBITDA margin).
- Gross margin expanded to 71.4% in Q4, up 14.3 percentage points YoY, due to higher ASPs and reduced cost of goods sold (COGS) per test.
- Launched expanded Fetal Antigen NIPT and first-and-only Platelet Fetal Antigen NIPT, along with Northstar PGx and CH add-ons, enhancing prenatal and oncology offerings.
- Signed a landmark in-network contract with UnitedHealthcare, eliminating friction for providers and patients while maintaining or increasing ASPs.

**【CFO Financial Commentary】**
- Q4 2025 GAAP net income was $4.4 million ($0.11 per diluted share), compared to a net loss of $11.5 million in Q4 2024.
- Full-year 2025 operating income of $16.0 million (5% margin) and adjusted EBITDA of $38.8 million (13% margin) highlighted operational efficiency.
- 2026 guidance: Total revenue of $430-445 million (41-46% YoY growth), with continued positive GAAP operating income.
- Strong balance sheet with $496 million in cash and $50 million in term debt.

**【Q&A Highlights】**
- **UnitedHealthcare Contract**: Effective April 2026, expected to boost test volume and ASPs without compromising margins.
- **Health System Integrations**: Potential for 10,000-30,000 annual tests per large health system, though not reflected in 2026 guidance.
- **Oncology Growth**: Northstar Select PGx and CH add-ons enhance value for oncologists, with Northstar Response MolDX coverage submission pending.
- **Sales Team Expansion**: Prenatal reps to grow from 150 to 185, oncology reps from 45 to 65 by year-end, balancing growth with service quality.
- **Competitive Landscape**: No material impact from competitors like Natera, with Q4 active ordering providers increasing significantly.


BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: Q3 2025 revenue $83.5M (+117% YoY), driven by 51% test volume growth and 44% ASP increase.
- **Profitability Breakthrough**: 70% gross margin, first positive GAAP net income ($1.5M), and $7.9M cash flow after capex.
- **Strategic Wins**: $314M IPO funds fueling EMR integration (Epic Aura) for health system adoption, and 664% oncology revenue growth.
- **2026 Milestones**: Northstar Response Medicare coverage by end-2026, MRD launch Q4 2026, and >$286M net IPO proceeds for growth.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $83.5 million, up 117% YoY, driven by 51% test volume growth and 44% ASP increase. Oncology revenue surged 664% YoY to $8.7 million.
- **Gross Margin Expansion**: 70% gross margin (Q3 2025) vs. 53% YoY, due to ASP growth and 10% COGS reduction to $151/test.
- **Strategic Investments**: $314M IPO proceeds to fund EMR integration (Epic Aura), targeting 9-month rollout to accelerate health system adoption.
- **Market Opportunity**: $100B+ U.S. market addressable with smNGS tech; prenatal/oncology ASPs poised for further growth via Medicaid PLA code expansion.

**【CFO Financial Commentary】**
- **Revenue Performance**: Q3 2025 total revenue $83.5M (117% YoY), with 101% prenatal growth ($74.8M) and 664% oncology growth ($8.7M).
- **Profitability**: GAAP operating margin 11.5% (Q3 2025), first positive GAAP net income ($1.5M) and cash flow ($7.9M after capex).
- **Guidance**: 2025 revenue $293-299M (92-96% YoY), Q4 2025 $84-90M (86-100% YoY), with >$286M net IPO proceeds.

**【Q&A Key Highlights】**
- **2026 Outlook**: Maintain GAAP profitability, invest in oncology coverage (Northstar Response Medicare MolDX by end-2026), and MRD launch targeting tumor-naive pan-cancer assay Q4 2026.
- **Sales Expansion**: Prenatal sales reps +8-10Q/Q, oncology +4-7Q/Q, supporting 25% Q/Q revenue growth.
- **Competitive Position**: No impact from competitor launches; UNITY Fetal Risk Screen ASPs up 10% Q/Q via Medicaid PLA code adoption.
- **MRD Differentiation**: smNGS tech enables tumor-naive MRD at 10PPM sensitivity, vs. competitors' tumor-informed approaches.

Actual	0.1	0.11
Forecast	0.1395	0.0602
Surprise	-28.32%	+82.72%

Actual	83.50M	96.05M
Forecast	82.90M	87.19M
Surprise	+0.72%	+10.17%

BLLN

BLLN fundamentals

BLLN Q4 2025 Earnings

Earnings Call

You can ask Aime

BLLN

BLLN fundamentals

BLLN Q4 2025 Earnings

Earnings Call

BLLN Earnings Call Summary for Q4/20254:30 PM on Mar 4, 2026

BLLN Earnings Call Summary for Q3/20254:30 PM on Dec 9, 2025

You can ask Aime